Arcxis Biotechnologies was an early-stage molecular diagnostics company developing, producing and distributing state-of-the-art portable biological real-time diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents in a highly multiplexed and flexible format. With key technologies licensed fromSandiaN ational Labs, the firms products and technologies include materials and microfluidics, sample preparation, assay development and automation solutions. The automation solutions include extraction, isolation, purification, amplification, hybridization, detection and reporting. Likely a victim of the 2008-9 recession, the IP and assets of the firm were sold in 2010 primarily to Fluidigm with all the principals now employed elsewhere.
